L-NAME Hydrochloride: Benchmark NOS Inhibitor for Vascular Research

Executive Summary: L-NAME Hydrochloride (NG-nitro-L-arginine methyl ester) is a potent, competitive inhibitor of nitric oxide synthase (NOS) with an IC₅₀ of approximately 70 μM [APExBIO]. It is widely used to suppress nitric oxide (NO) production, enabling detailed studies of vascular tone regulation, hypertension, and NO-mediated signaling pathways [Yamada et al., 2010]. L-NAME Hydrochloride acts in a dose-dependent manner in both cellular and animal models, and its effects are reversible by L-arginine supplementation [internal]. The compound is water- and DMSO-soluble but insoluble in ethanol, with operational storage at -20°C. Application boundaries and experimental caveats are clarified below to maximize rigor in NO pathway research.

Biological Rationale

Nitric oxide (NO) is a gaseous signaling molecule essential for vascular homeostasis, neurotransmission, and inflammatory modulation. NO is synthesized endogenously by nitric oxide synthase (NOS) enzymes, which exist as three isoforms: neuronal (nNOS), inducible (iNOS), and endothelial (eNOS). Endothelium-derived NO modulates vascular tone by promoting smooth muscle relaxation via cyclic GMP pathways. NO also influences gene transcription, post-translational modifications, and immune cell function.

Inhibition of NOS enables researchers to dissect NO's physiological and pathophysiological roles. L-NAME Hydrochloride selectively competes with L-arginine at the NOS active site, reducing NO production. This approach is foundational for models of hypertension, cardiovascular disease, and inflammatory signaling [internal]. Unlike non-selective inhibitors, L-NAME's competitive and reversible mechanism allows precise temporal control of NO signaling in both in vitro and in vivo systems.

Mechanism of Action of L-NAME Hydrochloride

L-NAME Hydrochloride (methyl (2S)-2-amino-5-[[amino(nitramido)methylidene]amino]pentanoate hydrochloride) is a structural analog of L-arginine. It competitively inhibits NOS by binding to its L-arginine substrate pocket, thereby blocking conversion of L-arginine to NO and citrulline [APExBIO]. This inhibition is dose-dependent, with reported IC₅₀ values for endothelial NOS of 70 μM in porcine aortic tissue assays (pH 7.4, 37°C, Krebs–Henseleit buffer).

In cell-based systems, L-NAME is typically administered at 1 mM for several days to achieve robust NOS inhibition. In animal models, intravenous dosing induces rapid, dose-dependent increases in systemic arterial blood pressure and bradycardia. These physiological effects are reversed by co-administration of L-arginine, confirming the competitive nature of inhibition. L-NAME also blocks acetylcholine-mediated endothelium-dependent relaxation in vascular ring assays, further verifying its on-target action.

Evidence & Benchmarks

• L-NAME Hydrochloride at 1 mM in cell culture models significantly reduces nitric oxide production and downstream gene expression (e.g., iNOS, COX-2) in high glucose-induced stress paradigms (APExBIO).
• Intravenous L-NAME (10–50 mg/kg) in rats causes dose-dependent increases in systemic arterial pressure and bradycardia, reversible by L-arginine supplementation (Yamada et al., 2010).
• L-NAME blocks Ca²⁺-dependent, endothelium-mediated vasorelaxation in porcine aortic strips at 70 μM, confirming inhibition of eNOS activity (internal).
• Vasorelaxing effects of anti-hypertensive peptides (e.g., rapakinin) are not fully blocked by L-NAME, indicating alternative NO-independent pathways for vascular relaxation (Yamada et al., 2010).
• Benchmarking studies show reproducible, dose-dependent NOS inhibition across multiple mammalian systems using APExBIO's L-NAME Hydrochloride (A7088) (internal).

Applications, Limits & Misconceptions

L-NAME Hydrochloride is essential for probing NO signaling in vascular tone regulation, hypertension, and cardiovascular disease models. It is utilized in both acute and chronic studies, including ex vivo vascular ring assays, in vivo blood pressure monitoring, and cell-based investigations of gene regulation and apoptosis. The compound's competitive, reversible mechanism allows for controlled inhibition and subsequent rescue by L-arginine.

This article extends previous guides such as 'Precision NOS Inhibition in Advanced Vascular Research' by providing updated quantitative benchmarks and clarifying application boundaries, especially regarding alternative vasorelaxation mechanisms. It also updates the workflows discussed in 'A Benchmark NOS Inhibitor for Vascular Research' with new evidence from peptide vasorelaxation studies.

Common Pitfalls or Misconceptions

• L-NAME Hydrochloride is not selective for a single NOS isoform and inhibits eNOS, iNOS, and nNOS competitively.
• Vasorelaxation in some models (e.g., rapakinin-induced) may be partially or wholly independent of NO, thus not fully blocked by L-NAME [Yamada et al., 2010].
• Long-term storage of L-NAME solutions is not recommended; fresh preparation is required for reproducible results [APExBIO].
• L-NAME is insoluble in ethanol; improper solvent selection leads to precipitation and loss of activity.
• NO-independent pathways (e.g., prostaglandin- or CCK-mediated vasorelaxation) may confound results if not controlled for.

Workflow Integration & Parameters

Compound Sourcing & Handling: APExBIO supplies L-NAME Hydrochloride (A7088) as a solid. For optimal solubility, dissolve at ≥27 mg/mL in water or ≥23 mg/mL in DMSO. Store at -20°C; use freshly prepared solutions for experiments.

Experimental Parameters:

• Cell culture: 1 mM L-NAME for 24–96 hours to inhibit NO production and downstream gene expression.
• Animal dosing: 10–50 mg/kg intravenously to induce hypertension and bradycardia; monitor reversal by L-arginine.
• Vascular ring assays: 70 μM in Krebs–Henseleit buffer (pH 7.4, 37°C) for acute inhibition of endothelium-dependent relaxation.

Refer to the L-NAME Hydrochloride product page for lot-specific certificates of analysis and safety documentation. For nuanced application in alternative NO-independent vasorelaxation studies, see 'Strategic Applications of L-NAME Hydrochloride', which focuses on translational and clinical research strategy—a complement to the experimental focus here.

Conclusion & Outlook

L-NAME Hydrochloride remains the benchmark NOS inhibitor for mechanistic studies of NO signaling, vascular tone, and hypertension. Its competitive action, reversibility, and robust dose-response make it indispensable for both basic and translational cardiovascular research. However, researchers must be aware of its non-isoform selectivity, solubility constraints, and the existence of alternative vasorelaxation pathways. Ongoing advances in peptide pharmacology and NO signaling necessitate continued benchmarking and critical evaluation of NOS inhibition strategies. For further details and ordering information, consult the APExBIO L-NAME Hydrochloride (A7088) product page.